Merck & Co., Inc. (NYSE: MRK) is a Healthcare company,
ranked #5,769 of 6,774 companies globally and #3,201 of 4,000 in United States on PositoAI,
with a Positivity Score of 15,578.
Its market capitalisation is ₹34.29 lakh Cr ($363.27B), P/E ratio is 116.9 and P/B ratio is 8.66.
It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
P/B Ratio8.66
P/E Ratio116.9
D/E Ratio1.28
ROE6.96%
Owes vs Owns ?0.68× Moderate$0.68 owed for every $1 it owns · balance sheet Jun 2026
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo,…
What is Merck & Co., Inc.'s P/E and P/B ratio?
Merck & Co., Inc. has a P/E ratio of 116.9 and a P/B ratio of 8.66.
What is Merck & Co., Inc.'s debt-to-equity ratio?
Merck & Co., Inc. has a debt-to-equity ratio of 1.28.
How much does Merck & Co., Inc. owe compared with what it owns?
Merck & Co., Inc. owes $0.68 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Merck & Co., Inc.'s Positivity rank?
Merck & Co., Inc. is ranked #5,769 of 6,774 companies globally and #3,201 of 4,000 in United States on PositoAI, with a Positivity Score of 15,578.
Does Merck & Co., Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Merck & Co., Inc..
Where can I read the latest news about Merck & Co., Inc.?
Recent headlines about Merck & Co., Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Merck & Co., Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Merck & Co., Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.
0 / 1000
🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.
Disclaimer —
PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.